User:Mr. Ibrahem/Oprelvekin
| Clinical data | |
|---|---|
| Trade names | Neumega |
| Other names | Recombinant human interleukin-11 (rHuIL-11) |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Interleukin 11 (IL-11)[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | >80% (s.c. application) |
| Metabolism | mainly renal |
| Onset of action | 5 to 9 days[1] |
| Elimination half-life | 6.9 ± 1.7h |
| Duration of action | 7 days[1] |
| Identifiers | |
| Chemical and physical data | |
| Formula | C854H1411N253O235S2 |
| Molar mass | approx. 19,000 g/mol g·mol−1 |
  (what is this?) (verify) | |
Oprelvekin, sold under the brand name Neumega is a medication used to prevent low platelets due to chemotherapy.[1] It is given by injection under the skin.[1] Effects begin after around 7 days and continue for about 7 days after the last dose.[1]
Common side effects include swelling, fast heart rate, shortness of breath, and red eyes.[1] Other side effects may include anaphylaxis, heart failure, and atrial fibrillation.[1] It is a recombinant form of interleukin 11 (IL-11) which primarily stimulates the production of platelets.[1]
Oprelvekin was approved for medical use in the United States in 1997.[2] In the United States it costs about 470 USD per 5 mg vial as of 2021.[3] In Canada it is available via a special access program.[4]
References[edit]
- ^ a b c d e f g h i j k l "Oprelvekin Monograph for Professionals". Drugs.com. Archived from the original on 25 August 2019. Retrieved 8 November 2021.
- ^ "CBER, Approval letter, Oprelvekin, prevention of severe thrombocytopenia, reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies, Genetics Institute, Inc". www.accessdata.fda.gov. Archived from the original on 8 November 2021. Retrieved 8 November 2021.
- ^ "Neumega Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 8 November 2021.
- ^ "Oprelvekin (SPECIAL ACCESS PROGRAM) | CHEO ED Outreach". outreach.cheo.on.ca. Archived from the original on 8 November 2021. Retrieved 8 November 2021.